Mixed Connective Tissue Disease, Sjogren Syndrome
Conditions
Keywords
Sicca Syndrome, Sjogren Syndrome, Connective Tissue Disease, Mixed, MCTD, Sharp Syndrome
Brief summary
This study was a basket trial designed to establish safety, tolerability and efficacy of MHV370 in Sjögren's Syndrome (SjS) and Mixed Connective Tissue Disease (MCTD).
Detailed description
This was a randomized, participant and investigator blinded, placebo-controlled, multi center parallel group basket study to evaluate the safety, tolerability and efficacy of MHV370 in participants with Sjögren's Syndrome (SjS) or with Mixed Connective Tissue Disease (MCTD). Participants first underwent a screening period of up to 6 weeks, followed by a treatment duration of 24 weeks and a follow-up period of 4 weeks. Total study duration for each participant was up to 34 weeks. Participants with SjS were randomized in a 1:1 ratio to MHV370 or placebo and participants with MCTD were randomized in a 1:1 ratio to MHV370 or placebo.
Interventions
DRUGMHV370
MHV370 for 24 weeks
DRUGPlacebo
Placebo for 24 weeks
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
SjS and MCTD: • Fully vaccinated with any locally approved COVID-19 vaccination including booster vaccinations if required by local guidelines SjS: * Unstimulated whole salivary flow rate of \> 0 mL/min at screening * Classification of Sjögren's Syndrome according to the 2016 ACR/EULAR criteria at screening * Screening ESSDAI (based on weighted score) ≥ 5 from 8 defined domains (biologic, hematologic, articular, cutaneous, glandular, lymphadenopathy, renal, constitutional). MCTD: * Diagnosis of MCTD based on criteria like a) Raynaud's phenomenon b) At least two of the four following signs: i) synovitis, ii) myositis, iii) swollen fingers and vi) interstitial lung disease * Patients with overlap syndromes, i.e. patients meeting diagnostic criteria for systemic autoimmune disease other than MCTD may be included unless they have major organ involvement as judged by the investigator
Exclusion criteria
SjS and MCTD: * Prior use of B-cell depleting therapy within 6 months of baseline. For participants who received B-cell depleting therapy within 6 -12 months of baseline visit, B-cell count should be within normal range * Prior treatment with any of the following within 3 months of baseline: CTLA4-Fc Ig (abatacept), Anti-TNF mAb, Intravenous Ig, Plasmapheresis, i.v. or oral cyclophosphamide, i.v. or oral cyclosporine A * Screening CBC laboratory values as follows: Hemoglobin levels \< 8 g/dL (\< 5 mmol/L), Total leukocyte count \< 2,000/µL (2 x 109/L), Platelets \< 50,000/µL (50 x 109/L), Neutrophil count \< 1,000/µL (1 x 109/L) * Pregnant or nursing (lactating) women * Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they use a highly effective method of contraception SjS: * Sjögren's Syndrome overlap syndromes where another autoimmune disease constitutes the primary illness * Required regular use of medications known to cause, as a major side effect, dry mouth / eyes Other protocol-defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| SjS Participants: Change From Baseline in Eular Sjögren's Disease Activity Index (ESSDAI) After 24 Weeks of Treatment | Baseline, Week 24 | The ESSDAI is an established disease outcome measure for Sjögren's syndrome that classifies disease activity in 3-4 levels according to their severity (i.e., no, low, moderate, high), over each of 12 organ-specific domains. These scores are then summed across the 12 domains in a weighted manner to provide the total score. The score range is 0 - 123, where a higher ESSDAI score indicates more severe symptoms. A negative change score from baseline indicates improvement. |
| MCTD Participants: Change From Baseline in Physician's Global Assessment Scale (PhGA) After 24 Weeks of Treatment | Baseline, Week 24 | The physician's global assessment scale is used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from no disease activity (0) to maximal disease activity (100). A negative change score from baseline indicates improvement. Only participants with evaluable records are included. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| SjS and MCTD Participants: Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours (AUC0-6h) of MHV370 | pre-dose, 0.5, 1, 2 ,4 and 6 hours after dosing at week 4 | The AUC from time zero to the 6-hours post-dose sampling time. Pharmacokinetic (PK) parameters were calculated based on MHV370 plasma concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1.0 ng/mL. AUClast was determined using non-compartmental methods. |
| SjS and MCTD Participants: Time to Reach Maximum Plasma Concentrations (Tmax) of MHV370 at Steady State | pre-dose, 0.5, 1, 2 ,4 and 6 hours after dosing at week 4 | Tmax is the time to reach maximum (peak) plasma concentration of MHV370 after single dose administration. Pharmacokinetic (PK) parameters were calculated based on MHV370 plasma concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1.0 ng/mL. Tmax was determined using non-compartmental methods. |
| SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Baseline, Weeks 4, 8, 12, 20 and 24 | The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F v4) is a short, 13-item patient-reported measure, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where a higher FACIT-F score indicates more severe symptoms. A negative change score from baseline indicates improvement. |
| SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Baseline, Weeks 4, 8, 12, 20 and 24 | The physician's global assessment scale is used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from no disease activity (0) to maximal disease activity (100). A negative change score from baseline indicates improvement. |
| SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Baseline, Weeks 4, 8, 12, 20 and 24 | The ESSDAI is an established disease outcome measure for Sjögren's syndrome that classifies disease activity in 3-4 levels according to their severity (i.e., no, low, moderate, high), over each of 12 organ-specific domains. These scores are then summed across the 12 domains in a weighted manner to provide the total score. The score range is 0 - 123, where a higher ESSDAI score indicates more severe symptoms. A negative change score from baseline indicates improvement. |
| SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | baseline, weeks 4, 8, 12, 20 and 24 | The ESSPRI is an established disease outcome measure for Sjögren's syndrome. The ESSPRI is a patient-reported, subjective symptom index which consists of three questions covering the cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain (articular and/or muscular). The participant can assess severity of symptoms they experience on a single numerical scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable) for each of the three domains. The overall ESSPRI score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where a higher ESSPRI score indicates more severe symptoms. A negative change score from baseline indicates improvement. |
| SjS Participants: Change From Baseline to the Salivary Flow Rate | Baseline, Weeks 4, 12 and 24 | Unstimulated whole salivary fluid secretions were collected over 5 minutes from participants. All assessments were performed at a fixed time of the day to minimize fluctuations related to the circadian rhythm of salivary flow and composition. Participants were instructed not to eat, drink or smoke for 90 minutes before the assessment. The start time and end time of saliva collection were recorded to calculate the salivary flow rate per minute. Only participants with evaluable records are included. |
| SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Baseline, Week 4, 12 and 24 | STAR is a composite responder index, including in a single tool all main disease features, and designed for use as a key efficacy endpoint in SjS Domain Point Definition of response. Points are assigned in the following 5 domains, if the corresponding criteria are met: * Systemic activity, if decrease in clin ESSDAI ≥ 3 points: 3 points * Patient reported outcome, if decrease in ESSPRI ≥ 1 point or 15%: 3 points * Lacrimal gland function (assessed by Schirmer's test), if abnormal score at baseline: increase ≥ 5 mm from baseline OR if normal score at baseline: no change to abnormal: 1 point * Salivary gland function (assessed by unstimulated salivary flow), if increase ≥ 25% from baseline: 1 point * Biological (assessed by serum IgG levels), if decrease ≥ 10%: 1 point The Total Score is the sum of all 5 domain scores, ranging from 0 to 9 points. A STAR responder is defined as ≥ 5 points in the Total Score. |
| SjS Participants: Change From Baseline to the Schirmer's Test | Baseline, Week 4, 12 and 24 | Schirmer's test is used to determine whether the eye produces enough tears to keep it moist especially for those who suffer from dry eye syndrome. A strip is placed in the lower eyelid for 5 minutes to assess tear production. After 5 minutes, the filter paper is removed and the distance between the leading edge of wetness and the initial fold is measured, using a millimeter ruler. Tear deficiency is defined as \<5 mm wetting of the paper after 5 minutes. |
| MCTD Participants: Change From Baseline in Forced Vital Capacity (FVC) | Baseline, Week 12 | Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. A positive change from baseline is considered a favorable outcome. |
| MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Second (FEV1) of a Forced Breath | Baseline, Week 12 | FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. A positive change from baseline in FEV1 is considered a favourable outcome. |
| MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Two Seconds (FEV2) of a Forced Breath | Baseline, Week 12 | FEV2 (forced expiratory volume in two seconds) is the amount of air which can be forcibly exhaled from the lungs in the first two seconds of a forced exhalation, measured through spirometry testing. A positive change from baseline in FEV2 is considered a favourable outcome. |
| MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Three Seconds (FEV3) of a Forced Breath | Baseline, Week 12 | FEV3 (forced expiratory volume in three seconds) is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation, measured through spirometry testing. A positive change from baseline in FEV3 is considered a favourable outcome. |
| MCTD Participants: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) | Baseline, Week 24 | Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measurement to assess the ability of the lungs to transfer gas from inspired air to the bloodstream. Inhaled carbon monoxide (CO) is used for this test due to its high affinity for hemoglobin. During a ten-second breath-hold, DLCO measures uptake of CO per time per CO pressure. The outcome is presented as percentage of predicted DLCO value. |
| MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Baseline, Weeks 4, 8, 12 and 24 | The K-BILD questionnaire is a self-administered health-status questionnaire that has been developed in patients with interstitial lung diseases. It consists of 15 items in three domains: breathlessness and activities, psychological factors, and chest symptoms. Total scores range from 0 to 100, with higher scores representing better health status. |
| MCTD Participants: Change From Baseline in Raynaud's Condition Score (RCS) | Baseline, Weeks 4, 12 and 24 | The Raynaud's Condition score (RCS) is participant's rating of difficulty considering number of attacks, duration, amount of pain, numbness, or other symptoms caused in the fingers (including painful sores) due to the Raynaud's phenomenon and impact of Raynaud's alone on use of hands every day. An 11-point Likert scale is used to rate the difficulty caused by the condition with 0 = no difficulty and 10 = extreme difficulty. Participants are asked to select the number that best describes their difficulty, with higher score indicating worse condition. |
| MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Baseline, Weeks 4, 8, 12 and 24 | The ESSDAI is an established disease outcome measure for Sjögren's syndrome that classifies disease activity in 3-4 levels according to their severity (i.e., no, low, moderate, high), over each of 12 organ-specific domains. Participants with Mixed Connective Tissue Disease (MCTD) completed the articular (from 0 no activity to 3 high activity) and pulmonary (from 0 no activity to 3 high activity) domains of the ESSDAI only. For MCTD participants, the score range is 0-21, where a higher score indicates more severe symptoms. A negative change score from baseline indicates improvement. |
| SjS and MCTD Participants: Maximum Observed Plasma Concentrations (Cmax) of MHV370 at Steady State | pre-dose, 0.5, 1, 2 ,4 and 6 hours after dosing at week 4 | Cmax is the maximum (peak) observed plasma concentration of MHV370 after single dose administration. Pharmacokinetic (PK) parameters were calculated based on MHV370 plasma concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1.0 ng/mL. Cmax was determined using non-compartmental methods. |
Countries
China, Germany, Hungary, Poland, Spain, Taiwan
Participant flow
Recruitment details
Participants took part in 10 investigative sites in 6 countries/regions.
Pre-assignment details
There was a screening period of up to 6 weeks to assess participants eligibility.
Participants by arm
| Arm | Count |
|---|---|
| MHV370 200mg - SjS MHV370 200mg oral dose, twice daily. SjS participants. | 12 |
| Placebo - SjS Placebo oral dose, twice daily. SjS participants. | 14 |
| MHV370 200mg - MCTD MHV370 200mg oral dose, twice daily. MCTD participants. | 2 |
| Placebo - MCTD Placebo oral dose, twice daily. MCTD participants. | 2 |
| Total | 30 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 4 | 0 | 0 | 0 |
| Overall Study | Technical problems | 7 | 9 | 1 | 2 |
| Overall Study | Withdrawal by Subject | 1 | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | MHV370 200mg - SjS | Placebo - SjS | MHV370 200mg - MCTD | Placebo - MCTD | Total |
|---|---|---|---|---|---|
| Age, Continuous | 49.3 years STANDARD_DEVIATION 12.2 | 54.7 years STANDARD_DEVIATION 9.67 | 35.0 years STANDARD_DEVIATION 12.73 | 44.0 years STANDARD_DEVIATION 0 | 50.5 years STANDARD_DEVIATION 11.52 |
| Race/Ethnicity, Customized Asian | 3 Participants | 3 Participants | 0 Participants | 0 Participants | 6 Participants |
| Race/Ethnicity, Customized White | 9 Participants | 11 Participants | 2 Participants | 2 Participants | 24 Participants |
| Sex: Female, Male Female | 12 Participants | 14 Participants | 2 Participants | 2 Participants | 30 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk |
|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 12 | 0 / 14 | 0 / 2 | 0 / 2 | 0 / 30 |
| other Total, other adverse events | 12 / 12 | 12 / 14 | 1 / 2 | 2 / 2 | 27 / 30 |
| serious Total, serious adverse events | 0 / 12 | 0 / 14 | 0 / 2 | 1 / 2 | 1 / 30 |
Outcome results
Primary
MCTD Participants: Change From Baseline in Physician's Global Assessment Scale (PhGA) After 24 Weeks of Treatment
The physician's global assessment scale is used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from no disease activity (0) to maximal disease activity (100). A negative change score from baseline indicates improvement. Only participants with evaluable records are included.
Time frame: Baseline, Week 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. The data includes only participants who completed Week 24. Only participants with evaluable records are included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Physician's Global Assessment Scale (PhGA) After 24 Weeks of Treatment | -62.00 Score on scale |
Primary
SjS Participants: Change From Baseline in Eular Sjögren's Disease Activity Index (ESSDAI) After 24 Weeks of Treatment
The ESSDAI is an established disease outcome measure for Sjögren's syndrome that classifies disease activity in 3-4 levels according to their severity (i.e., no, low, moderate, high), over each of 12 organ-specific domains. These scores are then summed across the 12 domains in a weighted manner to provide the total score. The score range is 0 - 123, where a higher ESSDAI score indicates more severe symptoms. A negative change score from baseline indicates improvement.
Time frame: Baseline, Week 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. The data includes only participants who completed Week 24. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Disease Activity Index (ESSDAI) After 24 Weeks of Treatment | -4.39 Score on scale | Standard Error 2.41 |
Secondary
MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI)
The ESSDAI is an established disease outcome measure for Sjögren's syndrome that classifies disease activity in 3-4 levels according to their severity (i.e., no, low, moderate, high), over each of 12 organ-specific domains. Participants with Mixed Connective Tissue Disease (MCTD) completed the articular (from 0 no activity to 3 high activity) and pulmonary (from 0 no activity to 3 high activity) domains of the ESSDAI only. For MCTD participants, the score range is 0-21, where a higher score indicates more severe symptoms. A negative change score from baseline indicates improvement.
Time frame: Baseline, Weeks 4, 8, 12 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 24 - pulmonary | -1.00 Score on scale | — |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 4 - pulmonary | 0.00 Score on scale | Standard Deviation 0 |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 8 - pulmonary | -0.50 Score on scale | Standard Deviation 0.707 |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 12 - pulmonary | -1.00 Score on scale | — |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 4 - articular | 0.00 Score on scale | Standard Deviation 0 |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 8 - articular | -1.00 Score on scale | Standard Deviation 0 |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 12 - articular | -1.00 Score on scale | — |
| MHV370 200mg - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 24 - articular | -2.00 Score on scale | — |
| Placebo - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 4 - articular | 0.00 Score on scale | — |
| Placebo - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 4 - pulmonary | 0.00 Score on scale | — |
| Placebo - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 8 - articular | 0.00 Score on scale | — |
| Placebo - SjS | MCTD: Change From Baseline in Articular and Pulmonary Domains of the Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 8 - pulmonary | 0.00 Score on scale | — |
Secondary
MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Second (FEV1) of a Forced Breath
FEV1 (forced expiratory volume in one second) is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. A positive change from baseline in FEV1 is considered a favourable outcome.
Time frame: Baseline, Week 12
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Second (FEV1) of a Forced Breath | 0.250 liters (L) |
Secondary
MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Three Seconds (FEV3) of a Forced Breath
FEV3 (forced expiratory volume in three seconds) is the amount of air which can be forcibly exhaled from the lungs in the first three seconds of a forced exhalation, measured through spirometry testing. A positive change from baseline in FEV3 is considered a favourable outcome.
Time frame: Baseline, Week 12
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Three Seconds (FEV3) of a Forced Breath | 0.460 liters (L) |
Secondary
MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Two Seconds (FEV2) of a Forced Breath
FEV2 (forced expiratory volume in two seconds) is the amount of air which can be forcibly exhaled from the lungs in the first two seconds of a forced exhalation, measured through spirometry testing. A positive change from baseline in FEV2 is considered a favourable outcome.
Time frame: Baseline, Week 12
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Forced Expiratory Volume During the First Two Seconds (FEV2) of a Forced Breath | 0.410 liters (L) |
Secondary
MCTD Participants: Change From Baseline in Forced Vital Capacity (FVC)
Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. A positive change from baseline is considered a favorable outcome.
Time frame: Baseline, Week 12
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) |
|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Forced Vital Capacity (FVC) | 0.530 liters (L) |
Secondary
MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD)
The K-BILD questionnaire is a self-administered health-status questionnaire that has been developed in patients with interstitial lung diseases. It consists of 15 items in three domains: breathlessness and activities, psychological factors, and chest symptoms. Total scores range from 0 to 100, with higher scores representing better health status.
Time frame: Baseline, Weeks 4, 8, 12 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Week 4 | 3.00 Score on scale | Standard Deviation 4.243 |
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Week 8 | 13.00 Score on scale | Standard Deviation 9.899 |
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Week 12 | 21.00 Score on scale | — |
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Week 24 | 58.00 Score on scale | — |
| Placebo - SjS | MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Week 4 | -2.00 Score on scale | — |
| Placebo - SjS | MCTD Participants: Change From Baseline in King's Brief Interstitial Lung Disease (K-BILD) | Week 8 | 0.00 Score on scale | — |
Secondary
MCTD Participants: Change From Baseline in Raynaud's Condition Score (RCS)
The Raynaud's Condition score (RCS) is participant's rating of difficulty considering number of attacks, duration, amount of pain, numbness, or other symptoms caused in the fingers (including painful sores) due to the Raynaud's phenomenon and impact of Raynaud's alone on use of hands every day. An 11-point Likert scale is used to rate the difficulty caused by the condition with 0 = no difficulty and 10 = extreme difficulty. Participants are asked to select the number that best describes their difficulty, with higher score indicating worse condition.
Time frame: Baseline, Weeks 4, 12 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Raynaud's Condition Score (RCS) | Week 4 | -2.50 Score on scale | Standard Deviation 3.536 |
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Raynaud's Condition Score (RCS) | Week 12 | -1.00 Score on scale | — |
| MHV370 200mg - SjS | MCTD Participants: Change From Baseline in Raynaud's Condition Score (RCS) | Week 24 | -2.00 Score on scale | — |
| Placebo - SjS | MCTD Participants: Change From Baseline in Raynaud's Condition Score (RCS) | Week 4 | 1.00 Score on scale | — |
Secondary
MCTD Participants: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO)
Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measurement to assess the ability of the lungs to transfer gas from inspired air to the bloodstream. Inhaled carbon monoxide (CO) is used for this test due to its high affinity for hemoglobin. During a ten-second breath-hold, DLCO measures uptake of CO per time per CO pressure. The outcome is presented as percentage of predicted DLCO value.
Time frame: Baseline, Week 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | MCTD Participants: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) | Baseline | 84.0 percentage of predicted DLCO | — |
| Placebo - SjS | MCTD Participants: Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) | Baseline | 95.5 percentage of predicted DLCO | Standard Deviation 2.12 |
Secondary
SjS and MCTD Participants: Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours (AUC0-6h) of MHV370
The AUC from time zero to the 6-hours post-dose sampling time. Pharmacokinetic (PK) parameters were calculated based on MHV370 plasma concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1.0 ng/mL. AUClast was determined using non-compartmental methods.
Time frame: pre-dose, 0.5, 1, 2 ,4 and 6 hours after dosing at week 4
Population: The pharmacokinetic (PK) analysis set included participants with at least one available valid (i.e., not flagged for exclusion) PK concentration measurement, who received MHV370 and with no protocol deviations with impact on PK data. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MHV370 200mg - SjS | SjS and MCTD Participants: Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours (AUC0-6h) of MHV370 | 1060 ng*h/mL | Standard Deviation 462 |
| Placebo - SjS | SjS and MCTD Participants: Area Under the Plasma Concentration-time Curve From Time Zero to 6 Hours (AUC0-6h) of MHV370 | 742 ng*h/mL | — |
Secondary
SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale
The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F v4) is a short, 13-item patient-reported measure, easy-to-administer tool that measures an individual's level of fatigue during their usual daily activities over the past week. The level of fatigue is measured on a 5-point Likert scale (0 = not at all, 1 = a little bit, 2 = somewhat, 3 = quite a bit, 4 = very much). To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where a higher FACIT-F score indicates more severe symptoms. A negative change score from baseline indicates improvement.
Time frame: Baseline, Weeks 4, 8, 12, 20 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 4 | 0.13 Score on scale | Standard Deviation 3.271 |
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 8 | 3.14 Score on scale | Standard Deviation 5.928 |
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 12 | -1.25 Score on scale | Standard Deviation 6.702 |
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 20 | -9.42 Score on scale | — |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 12 | 2.71 Score on scale | Standard Deviation 8.826 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 8 | -2.80 Score on scale | Standard Deviation 4.185 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 4 | -1.58 Score on scale | Standard Deviation 6.052 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 20 | 4.80 Score on scale | Standard Deviation 8.758 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 24 | 5.75 Score on scale | Standard Deviation 10.782 |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 20 | 23.00 Score on scale | — |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 8 | 20.00 Score on scale | Standard Deviation 7.071 |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 12 | 20.00 Score on scale | — |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 24 | 30.00 Score on scale | — |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 4 | 15.50 Score on scale | Standard Deviation 9.192 |
| Placebo - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 4 | -3.00 Score on scale | — |
| Placebo - MCTD | SjS and MCTD Participants: Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale | Week 8 | -2.00 Score on scale | — |
Secondary
SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA)
The physician's global assessment scale is used for the Investigator to rate the disease activity of their patient using 100 mm visual analog scale (VAS) ranging from no disease activity (0) to maximal disease activity (100). A negative change score from baseline indicates improvement.
Time frame: Baseline, Weeks 4, 8, 12, 20 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Data from participants who have discontinued treatment early are regarded as missing after the treatment discontinuation. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 4 | -1.75 Score on scale | Standard Deviation 12.658 |
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 8 | 2.57 Score on scale | Standard Deviation 12.608 |
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 12 | -4.00 Score on scale | Standard Deviation 20.559 |
| MHV370 200mg - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 20 | 3.00 Score on scale | — |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 12 | -19.43 Score on scale | Standard Deviation 14.328 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 4 | -5.25 Score on scale | Standard Deviation 11.185 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 24 | -30.75 Score on scale | Standard Deviation 19.534 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 20 | -14.60 Score on scale | Standard Deviation 22.423 |
| Placebo - SjS | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 8 | -8.90 Score on scale | Standard Deviation 11.474 |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 20 | -64.00 Score on scale | — |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 8 | -39.00 Score on scale | Standard Deviation 18.385 |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 24 | -62.00 Score on scale | — |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 12 | -66.00 Score on scale | — |
| MHV370 200mg - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 4 | -20.50 Score on scale | Standard Deviation 12.021 |
| Placebo - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 4 | -15.00 Score on scale | — |
| Placebo - MCTD | SjS and MCTD Participants: Change From Baseline in Physician Global Assessment (PhGA) | Week 8 | -12.50 Score on scale | — |
Secondary
SjS and MCTD Participants: Maximum Observed Plasma Concentrations (Cmax) of MHV370 at Steady State
Cmax is the maximum (peak) observed plasma concentration of MHV370 after single dose administration. Pharmacokinetic (PK) parameters were calculated based on MHV370 plasma concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1.0 ng/mL. Cmax was determined using non-compartmental methods.
Time frame: pre-dose, 0.5, 1, 2 ,4 and 6 hours after dosing at week 4
Population: The pharmacokinetic (PK) analysis set included participants with at least one available valid (i.e., not flagged for exclusion) PK concentration measurement, who received MHV370 and with no protocol deviations with impact on PK data. Only participants with evaluable records are included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| MHV370 200mg - SjS | SjS and MCTD Participants: Maximum Observed Plasma Concentrations (Cmax) of MHV370 at Steady State | 278 ng/mL | Standard Deviation 85.7 |
| Placebo - SjS | SjS and MCTD Participants: Maximum Observed Plasma Concentrations (Cmax) of MHV370 at Steady State | 194 ng/mL | — |
Secondary
SjS and MCTD Participants: Time to Reach Maximum Plasma Concentrations (Tmax) of MHV370 at Steady State
Tmax is the time to reach maximum (peak) plasma concentration of MHV370 after single dose administration. Pharmacokinetic (PK) parameters were calculated based on MHV370 plasma concentrations determined by a validated liquid chromatography and tandem mass spectrometry (LC-MS/MS) method with a lower limit of quantification of 1.0 ng/mL. Tmax was determined using non-compartmental methods.
Time frame: pre-dose, 0.5, 1, 2 ,4 and 6 hours after dosing at week 4
Population: The pharmacokinetic (PK) analysis set included participants with at least one available valid (i.e., not flagged for exclusion) PK concentration measurement, who received MHV370 and with no protocol deviations with impact on PK data. Only participants with evaluable records are included.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| MHV370 200mg - SjS | SjS and MCTD Participants: Time to Reach Maximum Plasma Concentrations (Tmax) of MHV370 at Steady State | 1.50 hours |
| Placebo - SjS | SjS and MCTD Participants: Time to Reach Maximum Plasma Concentrations (Tmax) of MHV370 at Steady State | 2.00 hours |
Secondary
SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI)
The ESSDAI is an established disease outcome measure for Sjögren's syndrome that classifies disease activity in 3-4 levels according to their severity (i.e., no, low, moderate, high), over each of 12 organ-specific domains. These scores are then summed across the 12 domains in a weighted manner to provide the total score. The score range is 0 - 123, where a higher ESSDAI score indicates more severe symptoms. A negative change score from baseline indicates improvement.
Time frame: Baseline, Weeks 4, 8, 12, 20 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 4 | -0.25 Score on scale | Standard Deviation 1.753 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 8 | 0.57 Score on scale | Standard Deviation 6.528 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 12 | -3.00 Score on scale | Standard Deviation 4.583 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 20 | -2.00 Score on scale | — |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 20 | 0.00 Score on scale | Standard Deviation 14.629 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 12 | -3.43 Score on scale | Standard Deviation 7.656 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 4 | -3.67 Score on scale | Standard Deviation 9.355 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 24 | -0.25 Score on scale | Standard Deviation 11.117 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Disease Activity Index (ESSDAI) | Week 8 | -4.80 Score on scale | Standard Deviation 11.487 |
Secondary
SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI)
The ESSPRI is an established disease outcome measure for Sjögren's syndrome. The ESSPRI is a patient-reported, subjective symptom index which consists of three questions covering the cardinal symptoms of Sjögren's syndrome: dryness, fatigue and pain (articular and/or muscular). The participant can assess severity of symptoms they experience on a single numerical scale of 0-10 (0 =no symptom at all and 10 = worst symptom imaginable) for each of the three domains. The overall ESSPRI score is calculated as the mean of the three individual domains where all domains carry the same weight. Minimum score can be 0 and maximum score can be 10, where a higher ESSPRI score indicates more severe symptoms. A negative change score from baseline indicates improvement.
Time frame: baseline, weeks 4, 8, 12, 20 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 4 | -0.12 Score on scale | Standard Deviation 0.354 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 8 | -0.67 Score on scale | Standard Deviation 0.793 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 12 | -0.42 Score on scale | Standard Deviation 0.5 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 20 | -0.17 Score on scale | — |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 20 | -2.20 Score on scale | Standard Deviation 1.865 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 12 | -1.38 Score on scale | Standard Deviation 1.976 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 4 | -0.53 Score on scale | Standard Deviation 1.105 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 24 | -2.00 Score on scale | Standard Deviation 2 |
| Placebo - SjS | SjS Participants: Change From Baseline in Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) | Week 8 | -0.37 Score on scale | Standard Deviation 1.511 |
Secondary
SjS Participants: Change From Baseline to the Salivary Flow Rate
Unstimulated whole salivary fluid secretions were collected over 5 minutes from participants. All assessments were performed at a fixed time of the day to minimize fluctuations related to the circadian rhythm of salivary flow and composition. Participants were instructed not to eat, drink or smoke for 90 minutes before the assessment. The start time and end time of saliva collection were recorded to calculate the salivary flow rate per minute. Only participants with evaluable records are included.
Time frame: Baseline, Weeks 4, 12 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | SjS Participants: Change From Baseline to the Salivary Flow Rate | Week 4 | 0.162 mL/min | Standard Deviation 0.2735 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline to the Salivary Flow Rate | Week 12 | 0.144 mL/min | Standard Deviation 0.2109 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Salivary Flow Rate | Week 4 | -0.127 mL/min | Standard Deviation 0.7914 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Salivary Flow Rate | Week 12 | 0.183 mL/min | Standard Deviation 0.3944 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Salivary Flow Rate | Week 24 | 0.564 mL/min | Standard Deviation 0.9193 |
Secondary
SjS Participants: Change From Baseline to the Schirmer's Test
Schirmer's test is used to determine whether the eye produces enough tears to keep it moist especially for those who suffer from dry eye syndrome. A strip is placed in the lower eyelid for 5 minutes to assess tear production. After 5 minutes, the filter paper is removed and the distance between the leading edge of wetness and the initial fold is measured, using a millimeter ruler. Tear deficiency is defined as \<5 mm wetting of the paper after 5 minutes.
Time frame: Baseline, Week 4, 12 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| MHV370 200mg - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 12, left eye | 2.0 milimeter | Standard Deviation 1.83 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 12, right eye | -1.0 milimeter | Standard Deviation 2.16 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 4, left eye | 1.1 milimeter | Standard Deviation 1.96 |
| MHV370 200mg - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 4, right eye | -1.5 milimeter | Standard Deviation 4.87 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 24, right eye | -3.0 milimeter | Standard Deviation 6.32 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 24, left eye | -1.0 milimeter | Standard Deviation 2.94 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 4, left eye | 1.6 milimeter | Standard Deviation 6.01 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 4, right eye | 0.0 milimeter | Standard Deviation 3.59 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 12, left eye | 4.9 milimeter | Standard Deviation 12.5 |
| Placebo - SjS | SjS Participants: Change From Baseline to the Schirmer's Test | Week 12, right eye | 5.3 milimeter | Standard Deviation 8.81 |
Secondary
SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24
STAR is a composite responder index, including in a single tool all main disease features, and designed for use as a key efficacy endpoint in SjS Domain Point Definition of response. Points are assigned in the following 5 domains, if the corresponding criteria are met: * Systemic activity, if decrease in clin ESSDAI ≥ 3 points: 3 points * Patient reported outcome, if decrease in ESSPRI ≥ 1 point or 15%: 3 points * Lacrimal gland function (assessed by Schirmer's test), if abnormal score at baseline: increase ≥ 5 mm from baseline OR if normal score at baseline: no change to abnormal: 1 point * Salivary gland function (assessed by unstimulated salivary flow), if increase ≥ 25% from baseline: 1 point * Biological (assessed by serum IgG levels), if decrease ≥ 10%: 1 point The Total Score is the sum of all 5 domain scores, ranging from 0 to 9 points. A STAR responder is defined as ≥ 5 points in the Total Score.
Time frame: Baseline, Week 4, 12 and 24
Population: The pharmacodynamic (PD) analysis set included all participants who received any study drug and had no protocol deviations with relevant impact on PD/efficacy data. Missing responses will be treated as non-responders. Only participants with evaluable records are included.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| MHV370 200mg - SjS | SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Week 4 | 0 Participants |
| MHV370 200mg - SjS | SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Week 12 | 1 Participants |
| MHV370 200mg - SjS | SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Week 24 | 0 Participants |
| Placebo - SjS | SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Week 4 | 3 Participants |
| Placebo - SjS | SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Week 12 | 4 Participants |
| Placebo - SjS | SjS Participants: Sjögren's Tool for Assessing Response (STAR) Response Over Time up to Week 24 | Week 24 | 2 Participants |